Fresenius Kabi Braced For ‘Pyrrhic Victory’ In Akorn Damages Lawsuit
As COVID-19 Takes A Bite Out Of Profit
Fresenius Kabi says a decision on damages stemming from its aborted takeover of troubled Akorn is expected imminently, but has underlined it will not reap enormous riches with a victory. Meanwhile, the German firm has just initiated Phase III trials for a key biosimilar candidate.
You may also be interested in...
As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.
Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.